PRQR

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a Dutch biopharmaceutical company founded in 2012 and headquartered in Leiden, the Netherlands. The company went public in September 2014 and specializes in developing RNA-based therapeutic treatments for rare genetic disorders. ProQR focuses primarily on inherited diseases that cause blindness and other serious genetic conditions, utilizing innovative RNA editing and antisense oligonucleotide technologies to address previously untreatable genetic mutations.